Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, Rachel Schiff, C. Kent Osborne et al.|Cancer Research|2008Cited by 494
Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor XenograftsChad J. Creighton, Rachel Schiff, Suleiman Massarweh et al.|Cancer Research|2008Cited by 138
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Rachel Schiff, Mario Giuliano et al.|Molecular Cancer Research|2016Cited by 49
Supplementary Figure 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Rachel Schiff, Mario Giuliano et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Rachel Schiff, Xiaoyong Fu et al.|Unknown|2023Cited by 0